Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
PLoS One. 2022 Jul 13;17(7):e0270908. doi: 10.1371/journal.pone.0270908. eCollection 2022.
Emerging resistance to colistin in Acinetobacter baumannii clinical strains is concerning because of the limited therapeutic choices for these important clinical pathogens. We studied the in vitro activities of different colistin-based antimicrobial agent combinations against colistin-resistant Acinetobacter baumannii. Fourteen clinical isolates of colistin-resistant Acinetobacter baumannii were obtained between 2015 and 2016. To identify colistin-based combinations with synergistic activities, multiple two antimicrobial combinations based on 8 commercially available drugs were evaluated by the checkerboard method. The most effective colistin-based combinations were vancomycin, aztreonam, ceftazidime and imipenem which showed synergistic activities against all examined strains. Colistin-rifampin showed synergy against four strains. Colistin-tigecycline and colistin-amikacin mostly showed indifferent results. By using the checkerboard tests, we were able to find the most promising colistin-based combinations that may provide more therapeutic options against colistin-resistant Acinetobacter baumannii.
耐多粘菌素鲍曼不动杆菌临床株的耐药性不断出现令人担忧，因为这些重要的临床病原体的治疗选择有限。我们研究了不同多粘菌素为基础的抗菌药物组合对多粘菌素耐药鲍曼不动杆菌的体外活性。在 2015 年至 2016 年期间获得了 14 株多粘菌素耐药鲍曼不动杆菌的临床分离株。为了确定具有协同作用的多粘菌素组合，通过棋盘法评估了基于 8 种市售药物的多种两种抗菌药物组合。对所有检测菌株均显示协同作用的最有效的多粘菌素组合是万古霉素、氨曲南、头孢他啶和亚胺培南。多粘菌素-利福平对四种菌株显示协同作用。多粘菌素-替加环素和多粘菌素-阿米卡星主要表现为无关结果。通过棋盘试验，我们能够找到最有前途的多粘菌素组合，这可能为治疗多粘菌素耐药鲍曼不动杆菌提供更多的治疗选择。
